Life sciences news
-
Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial
Monday August 1st 2022
Read more
-
Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study and reports disease-modifying profile for Short Term DSR
Tuesday July 19th 2022
Read more
-
ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder
Tuesday July 5th 2022
Read more
-
MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis
Tuesday June 28th 2022
Read more
-
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis
Tuesday May 10th 2022
Read more
-
Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME)
Monday May 9th 2022
Read more
-
argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia
Thursday May 5th 2022
Read more
-
reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a
Tuesday May 3rd 2022
Read more
-
Become a flanders.bio member
Your news here?
-
Mithra announces improved consolidated topline results from Donesta® Phase 3 studies and launch of recruitment for the extension of European study
Thursday April 14th 2022
Read more
-
Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study
Tuesday April 5th 2022
Read more
-
Aligos Therapeutics selects drug candidate ALG-097558, a potent ritonavir-free oral protease inhibitor for the treatment and prevention of COVID-19
Tuesday April 5th 2022
Read more
More info?
Contact us
Ellen Telleir
Communication Coordinator
